A Multicenter, Open-label, Single-arm, Phase 4 Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil Mesylate Tablets in Chinese Adolescents (Aged From 12 to Less Than 18 Years) With Chronic Graft-versus-host Disease (cGVHD) Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Belumosudil (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacokinetics
- Sponsors Sanofi
- 15 Oct 2024 Planned End Date changed from 1 Apr 2026 to 4 May 2026.
- 15 Oct 2024 Planned primary completion date changed from 1 Apr 2026 to 4 May 2026.
- 15 Oct 2024 Planned initiation date changed from 7 Oct 2024 to 7 Nov 2024.